China Health Group (HKSE:08225) EBIT: HK$-16.86 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is China Health Group EBIT?

China Health Group HKSE:08225 EBIT is HK$-16.86 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

China Health Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-28.04 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-16.86 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Health Group's annualized ROC % for the quarter that ended in Dec. 2025 was -108.96%. China Health Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -159.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Health Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -33.54%.

China Health Group  (HKSE:08225) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China Health Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-56.07 * ( 1 - 6.09% )/( (60.668 + 35.979)/ 2 )
=-52.655337/48.3235
=-108.96 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=120.257 - 31.796 - ( 27.793 - max(0, 34.544 - 111.495+27.793))
=60.668

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=96.194 - 34.213 - ( 26.002 - max(0, 35.705 - 87.794+26.002))
=35.979

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

China Health Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-56.07/( ( (2.787 + max(47.003, 0)) + (2.564 + max(18.078, 0)) )/ 2 )
=-56.07/( ( 49.79 + 20.642 )/ 2 )
=-56.07/35.216
=-159.22 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(69.713 + 0 + 11.834) - (31.796 + 0 + 2.748)
=47.003

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.524 + 0 + 15.259) - (34.213 + 0 + 1.492)
=18.078

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China Health Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-16.857/50.263
=-33.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Health Group EBIT Related Terms

China Health Group EBIT Historical Data

* Premium members only.

The historical data trend for China Health Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Health Group EBIT Chart

China Health Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.08 -17.65 -63.80 -15.85 -16.74

China Health Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.25 9.33 -25.10 11.18 -28.04

HKSE:08225 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, China Health Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Health Group EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Health Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Health Group's EV-to-EBIT falls into.


China Health Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-16.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-16.86 Mil mean?
China Health Group (HKSE:08225) has a EBIT of HK$-16.86 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Health Group.
Is China Health Group's EBIT too high?
China Health Group's current EBIT is HK$-16.86 Mil.
How does China Health Group's EBIT compare to TMO and DHR?
China Health Group's EBIT of HK$-16.86 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Health Group. China Health Group's current EBIT is HK$-16.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:08225) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.21, compared to a current price of HK$0.08 — trading 61.4% below its estimated fair value. The current EBIT is HK$-16.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Health Group (HKSE:08225), the current EBIT is HK$-16.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China Health Group Business Description

Address Building 17, Jianwai SOHO, Chaoyang District, Beijing, CHN
China Health Group Inc is an investment holding company engaged in providing medical care facilities in the People's Republic of China. The company provides provision of post-launch market research, medical and medical market services (PM services), Provision of contracted pharmaceutical development services (PD services), Provision of contracted clinical research services (CR Services), drug technologies, and Other medical services. The majority of its revenue for the company comes from the provision of PM services.